Indication · GI, Urology & Nephrology
Bladder cancer
Last checked: Nov 19, 2026Source: FDA, ClinicalTrials.gov
Devices
112
Cleared or approved since 2000
PMA and De Novo
9
Higher-risk or first-of-kind devices
Breakthrough devices
0
Authorized through June 30, 2026
Recruiting device trials
20
153 device trials in all
Devices
112 devices. PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
- NMP22 BladderChek Test
Abbott Diagnostics Scarborough, Inc. · PMA · System, Test, Tumor Marker, For Detection Of Bladder Cancer · newest 2022 · 4 decisions
- KARL STORZ D-Light C PDD System
KARL STORZ Endoscopy-America, Inc. · PMA · Light Source System, Diagnostic Endoscopic · newest 2022 · 2 decisions
- Urovysion Bladder Cancer Kit
Abbott Molecular · PMA · Test, Fluorescence In Situ Hybridization (Fish), For Bladder Cancer Detection And Monitoring For Recurrence · newest 2014 · 2 decisions
57 more devices with a free account
Showing the first 60. Narrow by pathway, or open a device type below.
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
Istituto Oncologico Veneto IRCCSAcademic, hospital or other
NCT07948200 · 60 participants (planned) · Start Jan 31, 2027 · Primary completion Jan 31, 2029
Device: Bladder EpiCheck · For: Non-Muscle-Invasive Bladder Cancer
Sites: Padova, Italy
- The Vanguard Study: Testing a New Way to Screen for CancerPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT06995898 · 24,000 participants (planned) · Start Jun 18, 2025 · Primary completion Jan 31, 2029
Device: Device Usage · For: Bladder Carcinoma; Breast Carcinoma; Colorectal Carcinoma and 8 more
Sites: Pleasanton, California; San Diego, California; Cheyenne Wells, Colorado · 49 sites in all
- Analysis of Breath Volatile Organic Compounds Using Mass SpectrometryNot yet recruiting
University of OklahomaAcademic, hospital or other
NCT07732686 · 2,000 participants (planned) · Start Nov 2026 · Primary completion Nov 2027
Device: Proton Transfer Reaction Mass Spectrometry Analysis · For: Pancreas Cancer; Hepatocellular Carcinoma; Lung Cancer and 6 more
Sites: Oklahoma City, Oklahoma
150 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
- Cystoscope And Accessories, Flexible/Rigid (FAJ)58
- Electrode, Electrosurgical, Active, Urological (FAS)21
- Resectoscope (FJL)10
- Cystourethroscope (FBO)8
- System, Test, Tumor Marker, Monitoring, Bladder (MMW)5
- System, Test, Tumor Marker, For Detection Of Bladder Cancer (NAH)5
- Light Source System, Diagnostic Endoscopic (OAY)3
- System, Test, (Ihc), Tumor Marker, Monitoring, Bladder Cancer (NBK)1
- Test, Fluorescence In Situ Hybridization (Fish), For Bladder Cancer Detection And Monitoring For Recurrence (NSD)1
Research
- Device studies on bladder cancer across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.